MT Newswires
PureTech Health Completes End-of-Phase 2 Meeting With FDA for Deupirfenidone to Treat Idiopathic Pulmonary Fibrosis
➖
AI Sentiment
Neutral
5/10
PureTech Health plc News
Latest updates and market news for PRTC
3 news
Dec 3 - Dec 9, 2025
Page 1
Business Wire
PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
📈
AI Sentiment
Highly Positive
8/10
Business Wire
PureTech’s Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
📈
AI Sentiment
Highly Positive
9/10
Share this news page